Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00001760 |
Recruitment Status
:
Completed
First Posted
: November 4, 1999
Last Update Posted
: December 13, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Cytokine Production Patterns in Patients with Systemic Mastocytosis Compared with Atopic Dermatitis and Healthy Individuals
Summary: This study will examine how mast cells (cells involved in allergic reactions) migrate and multiply in the skin of patients with mastocytosis, a condition characterized by too many mast cells in the body. The mast cells tend to multiply in the skin, causing dark, itchy skin spots known as urticaria pigmentosa. This study will determine if the skin of patients with mastocytosis produces chemicals called cytokines that cause mast cells to migrate to the skin and multiply. The findings will be compared with those from normal volunteers and patients with atopic dermatitis, a skin disease characterized by recurrent itchy rash usually seen in people with a family history of allergies.
Healthy volunteers, patients with mastocytosis and patients with atopic dermatitis 18 years of age and older may be eligible for this study. Participants will have the following tests and procedures:
- Suction blisters - Two to eight small blisters will be raised on the forearm using gentle suction. The fluid in the blisters will be collected with a syringe to study the chemicals produced by the skin. The tops of the blisters may be removed for research.
- Template study - Patients with high cytokine content in the blister fluid may have a template study. For this procedure, a plastic block (template) with holes matching the blister sites is placed over the blistered area. The wells of the template are filled with salt water and the fluid is removed with a syringe at 3, 8 and/or 24 hours. Patients are hospitalized for 24 hours for this study.
- Skin biopsy - A skin biopsy will be done to correlate cytokine levels with the number of mast cells in the skin. An area of skin is numbed with an anesthetic and a small circular area about the size of a pencil eraser is removed, using a sharp cookie cutter-type instrument.
- Blood draw - About 4 tablespoons of blood will be drawn to compare the chemicals in the blood with those in the blister fluid. The blood will also be analyzed for a complete blood count, clotting factors and substances that may be elevated in people with allergies.
Condition or disease |
---|
Atopic Dermatitis Healthy Mastocytosis |
Study Type : | Observational |
Enrollment : | 40 participants |
Official Title: | Determination of Cytokine Production Patterns in the Skin of Patients With Systemic Mastocytosis and Atopic Dermatitis Using the Suction Blister Technique |
Study Start Date : | January 1998 |
Study Completion Date : | December 2001 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
General: Age equal to or greater than 18.
Access to a primary medical care provider outside of the NIH.
Able to give informed consent.
No history of malignancy or autoimmune disease such as rheumatoid arthritis, vasculitis, pyoderma gangrenosum, psoriasis.
No use of systemic corticosteroids within the past month.
No use of local corticosteroids at the proposed blistering site within the past month.
No evidence of current acute infection.
INR less than or equal to 1.5, PTT less than or equal to 40, platelet count greater than or equal to 100,000/mm(3).
No personal or family history of keloid formation.
Blood glucose less than or equal to 160.
No use of any investigative drugs within the past month.
No allergy to lidocaine.
Healthy volunteers must not have a history of atopic dermatitis, mastocytosis or chronic urticaria.
Mastocytosis: Histologic evidence of mast cell hyperplasia in at least one organ system.
Atopic Dermatitis: Must have at least 3 major and 3 minor criteria.
No history of mastocytosis.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001760
United States, Maryland | |
National Institute of Allergy and Infectious Diseases (NIAID) | |
Bethesda, Maryland, United States, 20892 |
Publications:
ClinicalTrials.gov Identifier: | NCT00001760 History of Changes |
Other Study ID Numbers: |
980049 98-I-0049 |
First Posted: | November 4, 1999 Key Record Dates |
Last Update Posted: | December 13, 2007 |
Last Verified: | December 2001 |
Keywords provided by National Institutes of Health Clinical Center (CC):
Stem Cell Factor Cytokine Chemokines Chemotaxis |
Mast Cells Normal Volunteer Systemic Mastocytosis Atopic Dermatitis |
Additional relevant MeSH terms:
Dermatitis Dermatitis, Atopic Eczema Mastocytosis Mastocytosis, Systemic Skin Diseases Skin Diseases, Genetic Genetic Diseases, Inborn |
Skin Diseases, Eczematous Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms |